Saphnelo Overtakes Benlysta in CLE as Biologics Gain Ground Ahead of 2027 Trials
Event summary
- Saphnelo (AstraZeneca) now leads Benlysta (GSK) in biologic prescribing for cutaneous lupus erythematosus (CLE) among U.S. dermatologists and rheumatologists.
- Adoption of Saphnelo has surged since 2023, driven by physician experience and upcoming 2027 trial results across multiple autoimmune indications.
- 71% of rheumatologists and 48% of dermatologists believe co-management of CLE patients could be improved.
- Physicians estimate 32% of CLE patients may progress to systemic lupus erythematosus (SLE), with dermatologists estimating half that rate.
The big picture
The shift toward biologics in CLE reflects broader trends in autoimmune treatment, where targeted therapies are increasingly preferred over traditional systemic agents. AstraZeneca’s Saphnelo is capitalizing on this shift ahead of critical trial data that could expand its use across multiple indications. The evolving treatment landscape underscores the need for better coordination between dermatology and rheumatology as CLE management becomes more complex.
What we're watching
- Pipeline Impact
- Whether Biogen’s litifilimab and EMD Serono’s enpatoran can capture significant CLE patient share if approved.
- Specialty Dynamics
- The pace at which dermatology-rheumatology co-management improves for CLE patients.
- Regulatory Catalysts
- How 2027 trial results for Saphnelo will affect its long-term positioning in CLE and other autoimmune indications.
Related topics